Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2016-11-02 Regulatory Filings
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Invitation to in-depth company update
Regulatory Filings Classification · 90% confidence The document is a short announcement (1060 chars) from PCI Biotech inviting stakeholders to an 'in-depth company update' scheduled for November 10, 2016. It explicitly states that the 'presentation materials will be published' later. This structure—announcing an upcoming event where materials will be shared, rather than containing the full report or presentation itself—strongly indicates that this is an announcement about a future report or presentation release. Given the context of an 'in-depth company update' presentation, the most fitting category is Investor Presentation (IP) if the materials were attached, but since this is only the INVITATION to the event where the presentation materials will be published, it functions as a general regulatory announcement regarding an upcoming event/material release. However, since the document is an invitation to an update event, and not the actual presentation (IP) or a general regulatory filing (RNS), the closest fit among the options that cover event announcements or material releases is often RPA if it were announcing the publication date of a report. Since this is an invitation to an event where materials will be presented, and it is not a standard regulatory form, it is best classified as a general Regulatory Filing (RNS) or potentially a precursor to an Investor Presentation (IP). Given the nature of inviting people to an update, and the short length, RNS is the safest fallback for non-standard announcements, although it is closely related to an Investor Presentation event. I will classify it as RNS as it is a general announcement about an upcoming event/update, not the presentation itself.
2016-11-02 English
PCI Biotech: Update on funding of further development
Share Issue/Capital Change Classification · 99% confidence The document is titled "PCI Biotech: Update on funding of further development" and explicitly discusses initiating a process to carry out a share issue in the range of NOK 40-50 million. It details how the proceeds will be used for regulatory interactions, completing clinical studies, and pursuing partnering opportunities. This content directly relates to fundraising, financing activities, and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (4208 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2016-10-27 English
PCI Biotech: Distribution of todays presentation at United European Gastroenterology Week
Investor Presentation Classification · 99% confidence The document text is a detailed presentation slide deck or summary focusing on the results of a 'PHASE I STUDY' involving 'PHOTOCHEMICAL INTERNALISATION (PCI)' for treating 'PERIHILAR CHOLANGIOCARCINOMA'. It includes sections on background, pre-clinical data, trial design (Phase I/II Dose Escalation Study), trial status (Dose escalation completed), and detailed trial results (radiology data, RECIST response rates). This structure, focusing on clinical trial methodology, safety, and efficacy data presentation, strongly aligns with an Investor Presentation (IP) or a detailed clinical study report summary intended for investors or medical professionals. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a short announcement (RPA/RNS). Given the depth of clinical data presentation, Investor Presentation (IP) is the most appropriate classification.
2016-10-17 English
PCI Biotech: Distribution of todays presentation at United European Gastroenterology Week
Investor Presentation Classification · 95% confidence The document is a short announcement (2752 characters) from PCI Biotech regarding the distribution of a presentation given at the United European Gastroenterology (UEG) Week. The text explicitly states that the presentation is 'attached' and provides details about the study and the conference. This fits the 'MENU VS MEAL' rule, indicating it is an announcement about the presentation material rather than the presentation itself or a comprehensive report. Since the content is an investor-facing presentation distributed at an event, the most appropriate classification is Investor Presentation (IP). However, because the document's primary function is to announce the availability/distribution of this presentation material, it strongly aligns with the definition of a Report Publication Announcement (RPA), which covers the announcement of published materials. Given the context of distributing a specific presentation, RPA is a strong fit, but IP describes the *content* being distributed. Since the text is an announcement *about* the presentation being distributed, RPA is technically more accurate based on the 'MENU VS MEAL' rule, but IP is also highly relevant as the core subject is an investor presentation. Given the structure, which is a press release announcing the availability of the presentation slides, RPA is the best fit for the *action* described, though IP describes the *attachment*. I will lean towards IP as the content is clearly an investor presentation, and RPA is often used for formal reports (like 10-K/IR). However, reviewing the definitions, IP is for the 'Detailed presentation for investors focusing on financials, strategy, and market position.' The document *is* announcing the distribution of that presentation. Let's re-evaluate: If the attached document *is* the presentation, then IP is correct. If this text is just a press release saying 'the presentation is attached,' RPA is correct. Since the text describes the presentation content and context, and it's short, it functions as an announcement of the presentation's release. I will classify it as Investor Presentation (IP) because the core subject matter is the presentation itself, which is a key investor document, and the announcement is merely the vehicle for its distribution.
2016-10-17 English
PCI Biotech: Results from the bile duct cancer study will be presented as late-breaking news at United European Gastroenterology Week
Regulatory Filings Classification · 95% confidence The document is a short announcement from PCI Biotech dated October 17, 2016, stating that results from a Phase I bile duct cancer study will be presented at the United European Gastroenterology (UEG) Week as late-breaking news. It details the presentation time, location, and the presenter. Since this is an announcement about an upcoming presentation of study results, and not the full financial report (10-K, IR) or a transcript of a call (CT), it best fits the category for general regulatory announcements or news releases that don't fit other specific financial categories. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-financial, operational/clinical update that is being disclosed to the market, especially since it mentions compliance with the Norwegian Securities Trading Act disclosure requirements. It is not an Earnings Release (ER) as it concerns clinical data, not financial performance.
2016-10-17 English
PCI Biotech to present phase I results at Nordic Life Science Days 2016
Investor Presentation Classification · 99% confidence The document is structured as a presentation, indicated by slide headers (e.g., "PCI BIOTECH AT A GLANCE", "PCI TECHNOLOGY", slide numbers, and speaker information at the end). It details the company's technology (PCI), clinical programs (fimaCHEM, fimaVACC), research collaborations, and includes forward-looking statements and disclaimers typical of investor materials. The content focuses on strategy, pipeline updates, and clinical data presentation, which strongly aligns with the definition of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT).
2016-09-13 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.